← Back to headlines
Novartis' Rhapsido Skin Disease Drug Approved by European Commission
Novartis has secured approval from the European Commission for its new drug, Rhapsido, intended for the treatment of skin diseases.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Airbus Seeks Sale of U.S. Space Unit to Bolster European Satellite Alliance
11m ago
Fed Chair Warsh Signals Potential Rate Hikes Amid Stubborn Inflation
1h ago
Temasek Backs Singapore Airlines’ Investment in Air India Amid Scrutiny
1h ago
Dolly Parton’s Business Strategy and Cultural Legacy Examined
1h ago